IGM生物科学面临分析师降级为“稳住”评级,尽管药物仍在发展。 IGM Biosciences faces analyst downgrades to a "Hold" rating, despite ongoing drug development.

IGM生物科学组织(IGM Sciences)看到分析师多次降级,导致一致的“坚持”评级,目标价格为5.50美元。 IGM Biosciences (IGMS) saw multiple downgrades from analysts, resulting in a consensus "Hold" rating with a target price of $5.50. BMO资本市场公司将其评级降至“市场表现”,目标价格为2.00美元,低于21.00美元。 BMO Capital Markets reduced its rating to "Market Perform," with a target price of $2.00, down from $21.00. 尽管有这些降级,该公司仍继续研制抗癌和自发免疫疾病的免疫膜球蛋白M抗体。 Despite these downgrades, the company continues developing Immunoglobulin M antibodies for cancer and autoimmune diseases. 最近的收入显示出股本和净差值的负回报,尽管机构投资者增加了其股权。 Recent earnings showed a negative return on equity and net margin, though institutional investors have increased their stakes.